Summit Therapeutics PLC Sponsored ADR Aktie News

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.

Three years ago, Summit Therapeutics (SMMT 1.26%) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.

Where can you find the next monster stocks? Check out the biotech space.

Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.

Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory pathways. Summit is doubling down on ivonescimab, expanding clinical collaborations and targeting a $90B...

One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal.

REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential dur...

With the way negative stock market sentiment  has piled up recently, short squeezes have generated some massive returns.